January 23-25, 2018

San Francisco, CA

REGISTER TO ATTEND NOW – SAVE $500

Morning Workshop
Tuesday, January 23rd 2018

09.00 - 12.00

Humanized Mice for Immuno-Oncology


Workshop Leader: James Keck, Senior Director for the Clinical Lab & In Vivo Pharmacology Services, The Jackson Laboratory



Understanding the interactions between human immune cells and tumors is paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses.

In this workshop you will find:


  • Evidence that humanized NSG™ and NSG™-SGM3 mice can support the growth of allogeneic human tumors
  • Human tumors respond to standard-of-care chemotherapeutics and to immune check-point inhibitors clinically proven to initiate cytotoxic activity towards the tumor
  • Tumor-bearing, humanized NSG™ and NSG™-SGM3 mice are a new and valuable preclinical testing platform for immunooncology

James Keck, Senior Director for the Clinical Lab & In Vivo Pharmacology Services, The Jackson Laboratory

8930 - James Keck, Senior Director, In Vivo Pharmacology at The Jackson Laboratory

Afternoon Workshop
Tuesday, January 23rd 2018

13.00 - 16.00

Models and methods for studying tumor heterogeneity and metastases


Workshop Leader: Joshua Breunig, Assistant Professor, Cedars-Sinai Medical Center Workshop Leader: Simon Knott, Assistant Professor & Associate Director, Center for Bioinformatics and Functional Genomics, Cedars Sinai Medical Center



The deadliest cancers are often characterized by significant intratumoral heterogeneity, which is often increased in metastases or recurrent tumors. Comprehending the mechanisms of heterogeneity and the patterns of divergence in tumor subtypes will be a significant factor in designing the next generation of anti-tumor therapeutics, including immunotherapies and small molecule inhibitors


In this workshop you will learn:

  • Emerging findings in primary patient samples and models regarding the striking heterogeneity in high-grade tumors
  • New methodologies for characterizing the emergence of intratumoral heterogeneity through the creation of lineage trees
  • State-of-the-art techniques for comparing metastatic populations to the original tumor

Joshua Breunig, Assistant Professor, Cedars-Sinai Medical Center

Joshua Breunig

Joshua Breunig, PhD, is an Assistant Professor at Cedars-Sinai Medical Center with a joint appointment in the Department of Medicine at the David Geffen School of Medicine at UCLA. Dr. Breunig received his Ph.D. from Yale University. Currently, he investigates the transcriptional regulation of neural precursor cells (NPCs) in the brain, specifically exploring the pathways governing the transformation of NPCs into brain tumor progenitors. Using a next generation brain tumor models, his lab introduces patient-specific mutations to create “personalized” tumors in immunocompetent animal models. Dr. Breunig is supported by funding from the American Cancer Society, and NIH/NCI.

Simon Knott, Assistant Professor & Associate Director, Center for Bioinformatics and Functional Genomics, Cedars Sinai Medical Center

8930 - Simon Knott

Simon Knott, PhD, is an assistant professor and associate director of the Center for Bioinformatics and Functional Genomics at Cedars Sinai Medical Center. Dr. Knott combines computational biology and functional genomics to elucidate the molecular mechanisms that drive cancer progression.  Work in his laboratory is focused on three main areas: heterogeneity in cancer cell populations and how it impacts disease outcome, hetero-cellular interactions that allow cancer cells to manipulate the tumor microenvironment to evade therapy, and the development of novel computational and molecular tools to study disease progression